October 24, 2018 / 3:11 PM / 20 days ago

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

(Reuters) - A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc’s patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen (BIIB.O) from future royalty payments to Forward.

Forward said in a statement it was disappointed with the ruling and considering its options. Biogen did not immediately respond to a request for comment.

The companies had been locked in a dispute over patents for dimethyl fumarate, the key active ingredient in Tecfidera, the leading oral MS treatment. Tecfidera had sales of about $4.2 billion in 2017.

Biogen’s Tecfidera exclusivity in the United States is secured through 2028 under the ruling.

In January 2017, Biogen took out an insurance policy against a potential defeat in the patent dispute, agreeing to pay Forward $1.25 billion to license the company’s patents covering MS drugs and gain a share of Forward’s intellectual property.

The 2017 agreement would have allowed Forward to receive additional royalty payments if it had won the Federal Circuit appeal.

Reporting by Jan Wolfe; Editing by Chizu Nomiyama and Paul Simao

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below